Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M

Tvardi Therapeutics, Inc.

Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
Authorized common shares reduced from 200,000,000 to 16,666,667; par value unchanged.
No fractional shares issued; cash payment will be made in lieu of fractional shares.
Proportionate adjustments made to stock options, equity plan reserves, and exercise prices.
Stockholder-approved at June 4, 2024 annual meeting; board approved specific ratio Dec 19, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.